Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002157 · ClinicalTrials.gov registry record · NA
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
A NA study, sponsored by Celgene Corporation.
- Completed
- Registry status
- NA
- Development phase
NCT00002157 is a NA study that has completed, run by Celgene Corporation.
The verdict
NCT00002157, a NA study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal placebo-controlled study.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002157
The ClinicalTrials.gov registry entry for NCT00002157 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00002157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002157 about?
NCT00002157 is a clinical study titled "Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome". To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal placebo-controlled study.
What is the current status of trial NCT00002157?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002157?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00002157?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.